Received the Certificate of Physician Credentials and the EMBA of Zhejiang University.

Mr. Wang founded Winhealth Pharma in 2006. Under his vision and leadership, Winhealth Pharma has been undergoing exponential growth and become a leading rare disease and branded specialty pharmaceutical company, serving patients with rare diseases and unmet medical needs in China and adjacent regions. Mr. Wang built Winhealth into a pharmaceutical company with full blown capabilities spanning all major cycles of the value chain, including portfolio, drug development, clinical research and commercialization.

Prior to founding Winhealth, Mr. Wang served as a Practicing Physician, and then worked at Guotai Junan Securities and Shenzhen Kangzhe Pharmaceutical (HK: 00867). He has extensive experience on general management, leadership and entrepreneurship.

Ms. Hu has extensive experience in financial management and daily operations.

Prior to joining Winhealth, she worked in HangZhi Machinery & Electronics Co., Ltd and Hangzhou Hangdong Lighting Equipment Co., Ltd.

MBA of McGill University

Joining Winhealth in Jan 2019, Mr. Hao brought a wide spectrum of experience and skill sets including strategic innovation, business development, model upgrades, business incubation of rare deseases.

Previously, he served as SVP of strategic development, GM for B2B business at 111 Inc. (NASDAQ: YI), building the nation-wide B2B pharmacy platform from 0 to 1 and participated in the company's IPO in 2018.

Prior to that, he served as the Co-CEO of Sinco Pharm (Hong Kong: 06833), VP and GM of the pharmaceutical business, Finance Director in China for Cardinal Health (NYSE: CAH). He is also a major participant and supported Cardinal Health's USD 470 mln acquisition of Zuellig Pharma in 2010.

He served as the Executive Director of Finance of Eli Lilly in Canada, and the Director of Financial Planning and Procurement for Eli Lilly in China.

MBA in Yale University, Bachelor of economics in Fudan University.

Mr. Jing has 10+ years of investment and capital market experience in healthcare industry in the U.S. and China.

Prior to joining Winhealth, he was the Managing Director for Healthcare Investments at Fosun International New York Office.

Prior to that, he worked at McKinsey (Consultant, Shanghai), Goldman Sachs (Medical Investment Banking Department , New York), and Novartis (CFO office, New Jersey).

Kevin Hu is a Partner at LYFE Capital, bringing over 18 years of healthcare experience to the team.

Prior to joining LYFE Capital, Kevin was the Vice President at BBI Life Sciences (HKG: 1035). Before that, Kevin worked in sales and marketing management at Sanofi, AstraZeneca and Huadong Medicine (SZ: 000963).

Kevin received the Master degree in Medical Pharmacology from Soochow University and EMBA from China Europe International Business School (CEIBS).

James Zhao is a Founding Partner and Managing Partner at LYFE Capital.

He has 20+ years of healthcare investment experience in China and US. As few Chinese professionals who are able to seamlessly integrate China and US resources, James is an important liaison between LYFE China and US sectors. Prior to founding LYFE, he built up the China practice for Vivo Capital as a Managing Partner. He also worked as a Consultant at the Monitor Group in Shanghai.

James attained his MBA from Olin School of business, Washington University in St. Louis and his masters of science in molecular biology from Vrijie University Brussels. He was initially trained in clinical medicine at West China University.